Regeneron skids on shortfall in Eylea sales

A shortfall in sales of Regeneron’s Eylea eye drug takes a bite out of the company’s third-quarter results
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.